BC
BIOR

Birchview Capital’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Birchview Capital’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,080
Closed -$410K – 69
2021
Q3 		$410K Hold
1,080
– – 0.28% 45
2021
Q2 		$964K Hold
1,080
– – 0.58% 32
2021
Q1 		$1.28M Buy
1,080
+80
+8% +$110K 0.76% 21
2020
Q4 		$1.33M Buy
+1,000
New +$1.47M 0.77% 21

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Birchview Capital's BIOR Position: Q4 2021 in Review

Birchview Capital sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q4 2021, closing a stake of 1,080 shares — an estimated $410K sold.

Birchview Capital first reported a position in BIOR in Q4 2020 and held it in 4 quarters. The position peaked at $1.33M in Q4 2020. 53 funds tracked by Wall St. Rank hold BIOR as of Q4 2021.

  • Birchview Capital reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Birchview Capital sold 1,080 Biora Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $410K.
  • Birchview Capital first reported a position in Biora Therapeutics, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Birchview Capital's Biora Therapeutics, Inc. Common Stock position peaked at $1.33M in Q4 2020.
  • 53 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Birchview Capital's 13F filing for Q4 2021, filed 14 Feb 2022.